Clinical Edge Journal Scan

aIL-6 more effective than bDMARDs in RA with knee joint involvement


 

Key clinical point: Anti-interleukin-6 (aIL-6) receptor antibody was more effective than other biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) with knee joint involvement but not in patients without knee joint involvement.

Major finding: At 12 weeks, treatment with aIL-6 significantly increased clinical disease activity index (CDAI) in patients with knee joint involvement compared with other bDMARDs ( P = .02). In patients without swollen knee joints, aIL-6 vs. other bDMARDs showed no significant difference in CDAI improvement ( P = .61).

Study details: Findings are from a retrospective analysis of 1,059 treatment courses in patients with RA from the ANSWER cohort who were treated with bDMARDs. The patients were categorized into those with (n=275; 323 bDMARDs treatment course) or without (n=561; 736 bDMARDs treatment course) joint knee involvement.

Disclosures: ANSWER Cohort was supported by grants from Abbie G.K., Asahi-Kasei Pharma, AYUMI Pharmaceutical Co., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Sanofi, UCB Japan Co. Ltd., and Teijin Healthcare Limited. The authors including the lead author reported receiving grants, consulting fees, speaker fees, and/or honoraria from various sources.

Source: Maeda Y et al. Rheumatol Int. 2021 Apr 26. doi: 10.1007/s00296-021-04862-y .

Recommended Reading

Gene variant confirmed as strong predictor of lung disease in RA
MDedge Rheumatology
Secondhand smoke in childhood and adulthood linked to increased risk of rheumatoid arthritis
MDedge Rheumatology
Patients with RA on rituximab at risk for worse COVID-19 outcomes
MDedge Rheumatology
Novel study links air pollution to increased risk of rheumatoid arthritis flares
MDedge Rheumatology
RA: ARCTIC REWIND findings do not support csDMARD dose tapering among patients in remission
MDedge Rheumatology
RA: Three doses of intravenous tranexamic acid more effective than single dose post-TKA
MDedge Rheumatology
Tofacitinib more effective than tocilizumab in bDMARD-naïve patients with methotrexate-refractory RA
MDedge Rheumatology
Early RA outcomes have improved in the current decade
MDedge Rheumatology
Rheumatoid meningitis should be considered with or without RA diagnosis
MDedge Rheumatology
MTX+LEF combo shows robust safety profile compared with other therapeutic regimens in RA
MDedge Rheumatology